

Ref. No: 250190821
From: Commercial
Date: 19/08/21
Subject: Treatment of blood disorders

REQUEST

I have a freedom of information request related to the treatment of certain blood disorders. I would greatly appreciate if you could answer the following questions.

Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:

- Doptelet (avatrombopag)
- Jakavi (ruxolitinib)
- Nplate (romiplostim)
- Revolade (eltrombopag)
- Tavlesse (fostamatinib)
- Hydroxycarbamide

Q2. In the last 6 months, how many patients has your trust treated for:

- Immune thrombocytopenia (ICD10 code D69.3)
- Myelofibrosis (ICD10 code D47.4)
- Myelofibrosis (ICD10 code D47.4) – patients over the age 65

Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:

- Mycophenolate mofetil
- Rituximab
- Surgery (splenectomy)

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
- Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?

Q5. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

Q6. Does you trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

RESPONSE

Q1.

Pharmacy Issues between 1st February 2021 – 31st July 2021

	Number of Patients
Doptelet (avatrombopag)	0
Jakavi (ruxolitinib)	13
Nplate (romiplostim)	*<5
Revolade (eltrombopag)	23
Tavlesse (fostamatinib)	0
Hydroxycarbamide	171

Please note *<5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.

Q2. 43 patients were discharged **with a diagnosis** of Immune thrombocytopenia from 01/02/2021 to 31/07/2021.

9 patients were discharged **with a diagnosis** of Myelofibrosis from 01/02/2021 to 31/07/2021.

8 of the 9 patients discharged **with a diagnosis** of Myelofibrosis from 01/02/2021 to 31/07/2021 were aged over 65.

(The Information Team are unable to identify 'treated 'as per the request).

Please note that the numbers provided in question 2 are patients and not discharges (as stated in the request) as some patients have had more than 1 inpatient stay with the same diagnoses.

Q3. Patient list attached to the e-mail for Pharmacy to complete.

The pharmacy system does not record indications therefore we do not hold this data.

Q4. Patient list attached to the e-mail for Pharmacy to complete.

The pharmacy system does not record indications therefore we do not hold this data.

Q5. Information Team are unable to provide asking the relevant Care Group to answer for Clinical Trials.

The Trust has no involvement in any trials for this condition.

Q6. Information Team are unable to provide asking the relevant Care Group to answer for Clinical Trials.

The Trust has no involvement in any trials for this condition.